Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-12-12)Premium Content

Sarepta Therapeutics Inc New (SRPT)

2014-12-09@17:35:58 ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Against Sarepta Therapeutics, Inc. to Recover Investor Losses -- SRPT (PMZ)

2014-12-09@15:32:16 ET
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT (PMZ)

2014-12-08@21:29:20 ET
MASS Communications Delivers Fully Diverse Voice & Data Solution for Biotech Firm, Sarepta Therapeutics (PMZ)

2014-12-08@18:45:04 ET
INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP (BIZ)

2014-12-08@04:18:14 ET
Acinetobacter Infections - Pipeline Review, H1 2014 (MTO)

2014-12-03@21:09:48 ET
Sarepta Therapeutics, Inc.Corporate Event Announcement Notice (WSH)

2014-12-02@21:06:25 ET
Sarepta Therapeutics, Inc.Corporate Event Announcement Notice (WSH)

2014-12-01@00:42:10 ET
Sarepta Therapeutics Plans Webcast and Conference Call (CLM)

2014-12-01@00:37:28 ET
Sarepta Therapeutics to Participate at Upcoming Conferences (CLM)

2014-11-26@07:10:43 ET
Prosensa Soars on $680M Buyout Offer from BioMarin (ZAX)

2014-11-26@03:56:35 ET
Sarepta Therapeutics initiates dosing in Duchenne muscular dystrophy study (DTM)

2014-11-24@16:30:12 ET
Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 (BIZ)

2014-11-24@07:00:28 ET
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences (BIZ)

2014-11-21@12:54:11 ET
Sarepta Therapeutics Q3 net loss decreases (DTM)

2014-11-21@00:54:03 ET
Eteplirsen Study Commences (CLM)

2014-11-19@09:31:00 ET
Critical Alerts For SunEdison, Invensense, JinkoSolar, Inovio Pharmaceuticals and Sarepta Therapeutics Released By InvestorsObserver (PRN)

2014-11-18@15:24:00 ET
Robbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Shareholders (PRN)

2014-11-18@09:15:04 ET
Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy (BIZ)

2014-11-17@05:17:00 ET
Sarepta Therapeutics initiates dosing in Duchenne muscular dystrophy study (DTM)

2014-11-17@02:04:29 ET
Sarepta Therapeutics Reports First Patient Dosed in Study of Eteplirsen (CLM)